Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP – Get Free Report) announced its earnings results on Friday. The company reported ($1.23) EPS for the quarter, topping analysts’ consensus estimates of ($2.01) by $0.78, Zacks reports.
Neuphoria Therapeutics Inc. – Common Stock Stock Up 5.2 %
Neuphoria Therapeutics Inc. – Common Stock stock traded up $0.24 during mid-day trading on Friday, hitting $4.84. The company’s stock had a trading volume of 61,450 shares, compared to its average volume of 1,079,810. Neuphoria Therapeutics Inc. – Common Stock has a one year low of $2.12 and a one year high of $15.96.
Analysts Set New Price Targets
Separately, HC Wainwright lifted their price objective on shares of Neuphoria Therapeutics Inc. – Common Stock from $8.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, February 4th.
About Neuphoria Therapeutics Inc. – Common Stock
Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Featured Articles
- Five stocks we like better than Neuphoria Therapeutics Inc. – Common Stock
- How to Calculate Options Profits
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Up 50% in January, Twilio’s Pullback Is the Time to Buy
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Receive News & Ratings for Neuphoria Therapeutics Inc. - Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics Inc. - Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
